Search Results



Your search for The ASCO Post matches 6379 pages

Showing 201 - 250


Erratum: Immunotherapy Combination Trial

In the August 25, 2017, issue of The ASCO Post, in the Patient's Corner column “On My Way to Hospice Care, Immunotherapy Saved My Life” (page 52), the combination regimen cited is not correct. Instead, the report should have noted only that the patient was participating in a phase I clinical trial...

hematologic malignancies

Recent FDA Actions Include New Formulation, Expanded Indications for Oncology-Hematology Drug Products

The U.S. Food and Drug Administration (FDA) recently granted approval to olaparib tablets (Lynparza) as a maintenance therapy for ovarian cancer and to inotuzumab ozogamicin (Besponsa), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....

Extraordinary Caregivers

The ASCO Post salutes the men and women of MD Anderson Cancer Center for their heroic actions and resilience during Hurricane Harvey. “Ride-out” teams of health-care professionals stayed at the cancer center throughout the days-long catastrophic weather event to maintain a safe and caring...

solid tumors
prostate cancer

Long-Term Follow-up of PIVOT Argues for Immediate Treatment of Men With Unfavorable-Risk and Possibly High-Volume, Low-Risk Prostate Cancer

The updated results of the PIVOT1 study—reported in The New England Journal of Medicine by Wilt et al and reviewed in this issue of The ASCO Post (page 20)—did not show a statistically significant difference between treatment and observation for the initial management approach to men with newly...

hematologic malignancies

Update on Hematopoietic Cell Transplant Includes New Data in HIV-Infected and Follicular Lymphoma Patients

New hematology research, presented at the Best of ASCO New Orleans meeting, may help to guide the use of stem cell transplant in hematologic malignancies. At the meeting, Guillermo Garcia-Manero, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and Tycel Phillips, MD, of the...

breast cancer

FDA Clears Mammography Device With Option for Patient-Assisted Compression

On September 1, the U.S. Food and Drug Administration (FDA) cleared the first 2D digital mammography system that allows patients to increase or decrease the amount of compression applied to their own breast before the mammogram x-ray is taken. “Regular mammograms are an important tool in...

leukemia

FDA Approves Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia

The U.S. Food and Drug Administration (FDA) today approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) whose tumors express the CD33 antigen. The drug was also approved for the treatment of patients aged 2 years and older with...

breast cancer

Genetic Variant May Significantly Lower Risk of Breast Cancer in Women With History of Preeclampsia

Researchers have demonstrated that women with a history of preeclampsia have as much as a 90% decrease in breast cancer risk if they carry a specific common gene variant. Further studies are now underway to determine the mechanism of this protection in an effort to develop new breast cancer...

multiple myeloma

FDA Statement Regarding Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma

On August 31, U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued the following statement: “Clinical trials play a critically important role in bringing to market innovative new therapies for patients facing life-threatening...

prostate cancer

Androgen-Deprivation Therapy May Be Associated With Higher Risk of Heart Failure in Early-Stage Prostate Cancer

Men with localized prostate cancer who received androgen-deprivation therapy were at significantly higher risk of heart failure than men who did not receive this therapy, according to a Kaiser Permanente study published by Haque et al in the British Journal of Cancer. In the past,...

skin cancer

Artificial Intelligence May Help With Earlier Detection of Skin Cancer

New technology being developed by researchers at the University of Waterloo and the Sunnybrook Research Institute is using artificial intelligence (AI) to help detect melanoma at earlier stages. The technology employs machine-learning software to analyze images of skin lesions and provide...

leukemia

FDA Approves First CAR T-Cell Therapy for Pediatric and Young Adult Patients With B-Cell Precursor ALL

Today, the U.S. Food and Drug Administration (FDA) issued what it has called a “historic action,” making the first gene therapy available in the United States. The FDA approved tisagenlecleucel (Kymriah) for certain pediatric and young adult patients with a form of acute lymphoblastic...

breast cancer

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer

On August 29, Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate, for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer...

kidney cancer

Tivozanib Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma

On August 28, AVEO Oncology announced that the European Commission (EC) has approved tivozanib (Fotivda) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland. Tivozanib is indicated for the first-line treatment of adult patients with...

multiple myeloma

Phase III ALCYONE Study of Daratumumab in Front-Line Treatment of Multiple Myeloma

On August 24, positive topline results were announced from the phase III ALCYONE study of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) vs VMP alone as front-line treatment for newly diagnosed patients who are not considered candidates for...

lymphoma

FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma

On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....

2018 Pershing Square Sohn Cancer Research Prize Opens for Applications on October 2, 2017

The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will begin accepting applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000 per year—for up...

breast cancer

FDA Approves Fulvestrant as Monotherapy for Expanded Use in Breast Cancer

On August 28, the U.S. Food and Drug Administration (FDA) approved fulvestrant (Faslodex) at 500 mg as monotherapy for expanded use in women with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who have gone through menopause...

issues in oncology
survivorship

HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors

The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...

palliative care

Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer

A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...

gastroesophageal cancer

Women More Likely Than Men to Experience Response After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer

Female patients with locally advanced esophageal cancer treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published by...

breast cancer
gynecologic cancers

Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers

Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...

colorectal cancer

African American Men Have Lowest Survival Rates Among Patients With Anal Cancer

Over the past 30 years, squamous cell carcinoma of the anus has been one of the few cancers with a steadily rising incidence in the United States, with the most rapid increase seen in black men. To further investigate this trend, researchers at the University of Texas Southwestern Medical Center...

colorectal cancer

Clinical Genomics Implements QIAGEN’s Tube Collection Technology for Colorectal Cancer Recurrence Assay

On August 21, Clinical Genomics announced they have implemented QIAGEN’s PAXgene circulating cell-free DNA tube blood sample collection in its Colvera colorectal cancer recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate...

breast cancer

Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative Breast Cancer: A Step in the Right Direction

IN A SINGLE-ARM multicenter trial reported by Bardia and colleagues1 and reviewed in this issue of The ASCO Post, the use of sacituzumab govitecan (IMMU-132) showed a response rate of 30% and a clinical benefit rate of 46% in heavily pretreated patients with metastatic triple-negative breast...

hematologic malignancies
leukemia

Early-Phase Study Finds Vitamin C May Activate TET2 Function

Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published by Cimmino et al in Cell....

breast cancer
issues in oncology

Comparison of Screening Recommendations for Mammography

When to initiate screening for breast cancer, how often to screen, and how long to screen are questions that continue to spark emotional debates. A new study compares the number of deaths that might be prevented as a result of three of the most widely discussed recommendations for screening...

Chi Van Dang, MD, PhD, Appointed Professor at the Wistar Institute

THE WISTAR INSTITUTE has announced the appointment of scientist, medical oncologist, and National Academy of Medicine member Chi Van Dang, MD, PhD, as Professor.  Dr. Dang, the Scientific Director of the Ludwig Institute for Cancer Research in New York, shapes scientific strategy at Ludwig, as...

lung cancer

Osimertinib for EGFR-Positive NSCLC: The Phase III FLAURA Trial

RECENTLY ANNOUNCED DATA from the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously...

Theodoros N. Teknos, MD, Named President and Scientific Officer of UH Seidman Cancer Center

UNIVERSITY HOSPITALS (UH) has announced the appointment of Theodoros N. Teknos, MD, as the new President and Scientific Officer of UH Seidman Cancer Center, effective October 1. He will take over from current UH Seidman President Nathan Levitan, MD, who has been in the position since 2008 and...

issues in oncology

Liquid Biopsies Identify Distinct Genomic Profiles With Potentially Targetable Alterations in Carcinoma of Unknown Primary

Next-generation sequencing of circulating tumor DNA (ctDNA) identified distinct genomic profiles with potentially targetable alterations in 99.7% of patients with carcinoma of unknown primary (CUP) who have detectable alterations, according to results published by Kato et al in Cancer Research....

solid tumors

Detection of Early-Stage Cancers With Circulating Tumor DNA

In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...

Carlos L. Arteaga, MD, Named Director of UT Southwestern Cancer Center

CARLOS L. ARTEAGA, MD, has been named Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at The UT Southwestern Medical Center in Dallas.  Roles and Research at Vanderbilt  DR. ARTEAGA IS CURRENTLY Director of the Center for Cancer Targeted...

Patricia Ganz, MD, Appointed Editor-in-Chief of JNCI

ON JULY 1, Patricia Ganz, MD, assumed editorial leadership of JNCI: Journal of the National Cancer Institute. As Editor-in-Chief, she is also responsible for JNCI Monographs.  Dr. Ganz is Director of Cancer Prevention & Control Research at the University of California Los Angeles (UCLA)’s...

prostate cancer

Brachytherapy for Prostate Cancer: An Old Form of Radiation Treatment That Is Still One of the Most Effective

BRACHYTHERAPY HAS a long track record in treating cancer, dating back to the first reported use of an implanted radioactive source in 1901, and brachytherapy for the treatment of prostate cancer dates back to 1914, when Pasteu and Degrais used a radium source inserted through a urethral catheter. ...

Team Aims to Apply CAR T-Cell Therapy to Pancreatic Cancer

STAND UP TO CANCER (SU2C) and Lustgarten Foundation for Pancreatic Cancer Research are supporting a new translational research team to explore how chimeric antigen receptor (CAR) T-cell therapy can be applied to pancreatic cancer. The approach uses specially modified immune cells to find and...

hepatobiliary cancer

Pursuing Combination Strategies With Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma

PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the incidence and...

symptom management

New ASCO Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment

AN UPDATE of the ASCO Clinical Practice Guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued by Hesketh et al in the Journal of Clinical Oncology,1 provides new evidence-based information on the appropriate use of olanzapine, neurokinin 1 (NK1)...

First Universal Childhood Cancer Data Lab Opens

ALEX’S LEMONADE STAND FOUNDATION (ALSF) has announced the opening of the first-of-its-kind Childhood Cancer Data Lab (CCDL) with the mission of accelerating cures. ALSF first announced the CCDL at the National Cancer Moonshot Summit in Washington, DC, hosted by former Vice President Joe Biden and...

World Oncology Leaders Reunion

 

gynecologic cancers

FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer

On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to...

leukemia

FDA Approves Inotuzumab Ozogamicin for Relapsed or Refractory B-Cell Precursor ALL

On August 17, 2017, the U.S. Food and Drug Administration (FDA) approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). INO-VATE ALL The approval was based on data from INO-VATE ALL, a randomized (1:1), ...

Reuben Shaw, PhD, Receives NCI Outstanding Investigator Award

Salk Institute for Biological Studies Professor Reuben Shaw, PhD, has received the National Cancer Institute (NCI) Outstanding Investigator Award, which encourages cancer research with breakthrough potential. Dr. Shaw, a member of Salk’s Molecular and Cell Biology Laboratory and holder of the...

Look for Opportunities to Lower Barriers to ­Participation of Older Patients in Oncology Clinical Trials

Practicing evidence-based medicine requires evidence, but the evidence for efficacy and safety of new and evolving cancer therapies in older adults is wanting due to their underrepresentation in oncology clinical trials. “It is difficult to practice evidence-based medicine in an older population...

geriatric oncology
issues in oncology

‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials

Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, noted in an interview with The ASCO Post. Prompting those changes are the rapidly...

Hospice and Palliative Medicine Fellowship Created at Fox Chase Cancer Center

The Pain & Palliative Care Program at Fox Chase Cancer Center is offering a new Hospice and Palliative Medicine fellowship in partnership with the Hospice of the Visiting Nurse Association of Greater Philadelphia and Temple University Hospital. The 1-year program is approved by the...

solid tumors
breast cancer

A Personal Tribute to Angela H. Brodie, PhD, a Scientist Who Transformed Breast Cancer Treatment

Angela H. Brodie, PhD, a pioneer in breast cancer research, passed away on June 7, 2017, from complications of Parkinson’s disease and pancreatic cancer. An obituary for Dr. Brodie was published previously in the June 25, 2017, issue of The ASCO Post. Here, Dr. Balkees Abderrahman shares a...

kidney cancer

CheckMate-214: Nivolumab and Ipilimumab in Intermediate- and Poor-Risk Previously Untreated Advanced or Metastatic RCC

On August 15, Bristol-Myers Squibb Company announced topline results from the CheckMate-214 trial investigating nivolumab (Opdivo) in combination with ipilimumab (Yervoy) vs sunitinib (Sutent) in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell...

lymphoma

FDA Accepts sBLA and Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell Lymphoma

On August 16, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL). The sBLA and its acceptance is based on data from the phase III...

Recent FDA Actions Include New Drug Approvals in Leukemia, Expanded Approvals in Colorectal Cancer and Graft-vs-Host Disease

The U.S. Food and Drug Administration (FDA) recently granted approval, expanded approval, and breakthrough therapy designation to numerous treatments across a range of tumor types and malignancies. New Drug Approvals Daunorubicin-Cytarabine Combination (Vyxeos): On August 3, the FDA granted...

Advertisement



Advertisement


Advertisement